Phosphate transport inhibitors
AssigneeGenzyme Corporation
InventorsThomas H. Jozefiak, Cecilia M. Bastos, Chad C. Huval
Life of this patent
Estimating the term…
Loading patent…
AssigneeGenzyme Corporation
InventorsThomas H. Jozefiak, Cecilia M. Bastos, Chad C. Huval
Estimating the term…
Disclosed is a phosphate transport inhibiting compound represented by Structural Formula (I): R1 and R2 are independently —H, an electron withdrawing group or a C1-C10 alkyl group. Y is a covalent bond, a substituted methylene group, an unsubstituted methylene group or —CR1R2P(O)(OH)—. R3 is a hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups, a substituted hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups, a heteroaryl group, a substituted heteroaryl group or a phenyl group substituted with one or more groups selected from —Cl, —Br, —F, —CN, —NO2, —ORa, —N(Ra)2, —COORa, —CON(Ra)2, —CORa, —S(O)Ra, —S(O)2Ra, —S(O)2N(Ra)2, —NRaS(O)2Ra, —NRaCORa, a halogenated lower alkyl group, an aryl group, a substituted aryl group, or a halogenated alkoxy group. Each Ra is independently —H, lower alkyl, substituted lower alkyl, aryl or substituted aryl. Each Rb is independently —H, a lower alkyl group, or a phosphate protecting group.
A pharmaceutical composition comprising:
A method of inhibiting phosphate transport in a subject in need of phosphate transport inhibition, said method comprising the step of administering to the subject an effective amount of a polyacrylate polymer comprising one or more pendant phosphinyl phosphonate groups or a pharmaceutically acceptable salt thereof or ester thereof.
Dependencies are inferred from the claim text.